Pharmacokinetics of Petrelintide in Participants With Impaired Hepatic Function

This clinical research trial is testing the investigational medicinal product (IMP) petrelintide that is being developed for body weight reduction in people living with obesity or overweight who have comorbidities. The aim of this clinical research trial is to investigate whether the pharmacokinetics (PK) of petrelintide will be different in people with hepatic impairment (HI) compared to people with normal hepatic function.

NCT Number	NCT07682818
Lead Sponsor	Zealand Pharma
Conditions	Impaired Hepatic Function
Enrollment	36 participants
Start Date	2026-05-18
Primary Completion	2027-04-12 (estimated)
Study Completion	2027-04-12 (estimated)
Updated on ClinicalTrials.gov	2026-07-06